In 1989, Carpentier pioneered work to use the patient's own skeletal muscle (the latimissus dorsi muscle) to repair the failing myocardium, a procedure known as cardiomyoplasty, which has since advanced into the exciting realms of tissue engineering science. In 2008, Carpentier announced a fully implantable artificial heart will be ready for clinical trial by 2011, and for alternative to transplant in 2013. It was developed and will be manufactured by him, Biomedical firm Carmat, and venture capital firm Truffle. The prototype uses electronic sensors and is made from chemically treated animal tissues, called "biomaterials," or a "pseudo-skin" of biosynthetic, microporous materials, amid another US team's prototype called 2005 MagScrew Total Artificial Heart, and Japan and South Korea researchers are racing to produce similar projects. The first clinical trial are under process since 2013.